Six of ten endocannabinoid system genes were dysregulated in inflamed IBD tissue, with some suppressed and others overexpressed, suggesting the system plays an active role in gut inflammation.
IBD patients interested in cannabinoid research, gastroenterologists, and endocannabinoid system researchers.
6 of 10 ECS genes dysregulated in inflamed IBD tissue
What the researchers found
In IBD patients, FAAH, PPARG, and TRPV1 were significantly downregulated in inflamed mucosa compared to non-inflamed tissue and controls. CB2 and GPR55 receptors were upregulated in inflamed tissue. These patterns were consistent across both Crohn's disease and ulcerative colitis.
Why it matters
Finding specific patterns of ECS gene dysregulation in inflamed gut tissue provides molecular evidence for why cannabinoid-based therapies might help IBD. The upregulation of CB2 receptors in inflamed tissue suggests the body is actively trying to use the endocannabinoid system to fight inflammation.
The numbers in context
FAAH downregulated in inflamed vs non-inflamed (p=0.012). PPARG downregulated (p=0.001). TRPV1 downregulated (p=0.032). CB2 upregulated (p=0.005). GPR55 upregulated (p=0.001). 6 of 10 ECS genes dysregulated.
How the study worked
Paired biopsies of inflamed and non-inflamed colonic mucosa from 30 IBD patients (17 UC, 13 CD) plus 17 non-IBD controls were analyzed using quantitative PCR for 10 endocannabinoid system genes.
What this study cannot tell us
Small sample size (30 IBD patients, 17 controls). Cross-sectional design cannot determine whether ECS changes cause or result from inflammation. Gene expression does not always correlate with protein levels or functional activity.
How to read the evidence
Original human tissue study with paired biopsies, but limited by small sample size and cross-sectional design.
When this study was published
2026 study.
The bigger picture
This study adds to mounting evidence that the endocannabinoid system is disrupted in IBD. The specific pattern of changes could guide which cannabinoid receptor targets might be most therapeutically relevant for different aspects of gut inflammation.
Questions still open
- Could targeting the upregulated CB2 receptors in inflamed gut tissue provide therapeutic benefit? Do these gene expression changes normalize when IBD is in remission?
Common questions
What does this mean for cannabis and IBD?
Why were some ECS genes up and others down?
Read the original research
Altered endocannabinoid system gene expression in inflammatory bowel disease mucosa: New perspectives in inflammatory bowel disease management.
World journal of gastrointestinal endoscopy, 18(2), 113576
Citation
Pelisenco, Iulia Andreea; Salvi, Alessandro; De Petro, Giuseppina; Musat, Ioana Andreea; Manuc, Teodora Ecaterina; Tieranu, Cristian George; Becheanu, Gabriel; Milanesi, Elena; Dobre, Maria. (2026). Altered endocannabinoid system gene expression in inflammatory bowel disease mucosa: New perspectives in inflammatory bowel disease management.. World journal of gastrointestinal endoscopy, 18(2), 113576. https://doi.org/10.4253/wjge.v18.i2.113576
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk